Navigation Links
Raydiance collaborates with Rutgers, MTF to develop innovative tissue processing approaches

Petaluma, CA and New Brunswick, NJ, November 19, 2007 Raydiance, Inc. today announced that is has entered into an innovative collaboration with Rutgers University and the Musculoskeletal Transplant Foundation (MTF), the nations largest tissue bank, to improve the science of dermal tissue processing.

In a first-of-its-kind test, world leading tissue engineers will utilize a new type of laser developed on the Raydiance Ultrashort Pulse (USP) laser platform to maximize the transplants processed from donated dermal tissue. As part of this process, the collaboration will explore new ways to use the transformational power and precision of the Raydiance laser, which can instantly vaporize material without heat or residual damage at very precise scales, down to a resolution of several microns.

The collaboration involves MTF as the project sponsor, Rutgers as the center for developing innovative tissue processing approaches and Raydiance as the core laser technology provider. Experts from all three parties will work towards providing more advanced technology that results in less expensive and faster solutions for those in need of skin transplants for burn, complicated hernia repair, and reconstructive procedures.

Dr. Zhixiong (James) Guo, principal investigator for Rutgers University, said, Having worked with lasers for years, the Raydiance laser platform is one hundred times more powerful than anything I have ever used before. Not only can it separate skin more precisely and effectively, but also it has the unique capability to decontaminate the surface of soft tissue. If our tests prove successful, we will be able to disrupt and reinvent dermal tissue processing as we know it. This is great news for burn victims as well as those suffering from cancer, degenerative joint disease, arthritis and other skin trauma.

Bruce Stroever, President and CEO of MTF, said Over 900,000 Americans receive tissue transplants each year, but many more are in need. Preparing human tissue grafts is a complex and meticulous process. An important part of our mission is the ability to maximize the number and type of transplanted tissues processed from the gift of donation. We believe the Raydiance technology has the potential to process human tissue much more efficiently, increasing the supply of scarce dermal tissues. This would result in more usable tissue, offering the benefit of better outcomes for more patients.

Scott Davison, President of Raydiance, said, We are delighted to work with Rutgers and MTF on this important project. The Raydiance USP laser platform is unlocking disruptive innovation across a range of industries, from materials science to next generation surgery to genomics. The unique challenges inherent in the way tissue is recovered today makes this is an excellent development category for our laser, one that truly plays to the strengths of Raydiance technology.

The initial phase of the project will focus on demonstrating the feasibility of USP laser processing of donor skin in the following areas:

  • Separation of donor skin layers - Develop non-invasive laser-ablation methods to separate the skins dermal and epidermal layers to improve and increase the usability and viability of limited donor tissues.

  • Surface decontamination Develop non-intrusive sterilization techniques on donor skin and tendons to minimize collateral tissue damage while effectively removing viral or bacterial contamination.

  • Removal of unwanted hairs - Develop a laser destruction method to effectively remove unwanted hair from donor tissue with minimal collateral tissue damage.


Contact: Carl Blesch
732-932-7084 x616
Rutgers University

Related biology news :

1. Gender, coupled with diabetes, affects vascular disease development
2. New target for anti-flu drug development
3. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
4. A new radiation therapy treatment developed for head and neck cancer patients
5. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
6. Princeton engineers develop low-cost recipe for patterning microchips
7. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
8. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
9. UCR engineers to develop new tool to measure how environmental exposures affect health
10. Researchers develop simple method to create natural drug products
11. Researchers developing device to predict proper light exposure for human health
Post Your Comments:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology: